The addition of Rituximab (R) to combination chemotherapy (CT) significantly improves the treatment of mantle cell lymphomas (MCL):: Results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG).

被引：0

作者：

Hiddemann, W ^{[1
]}

Unterhalt, M ^{[1
]}

Dreyling, M ^{[1
]}

Hossfeld, DK ^{[1
]}

Lengfelder, E ^{[1
]}

Metzner, B ^{[1
]}

Pfreundschuh, M ^{[1
]}

Kneba, M ^{[1
]}

Fricke, HJ ^{[1
]}

Böck, HP ^{[1
]}

Schmitz, N ^{[1
]}

Koch, P ^{[1
]}

Fuchs, R ^{[1
]}

机构：

[1] Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, GLSG, D-8000 Munich, Germany

来源：

BLOOD | 2002年 / 100卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

339

引用

页码：92A / 92A

页数：1

共 50 条

[1] The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymhoma but not in mantle cell lymphoma: Results of two prospective randomized studies of the German Low Grade Lymphoma Study Group (GLSG).
Hiddemann, W
Forstpointner, R
Kneba, M
Schmitz, N
Schmits, R
Metzner, B
Reiser, M
Lengfelder, E
Woermann, B
Harder, H
Hegewisch-Becker, S
Berdel, W
Hess, G
Eimermacher, H
Aldaoud, A
Planker, M
Parwaresch, R
Dreyling, M
Unterhalt, M
BLOOD, 2004, 104 (11) : 50A - 50A
[2] Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas:: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Hiddeman, W
Forstpointner, R
Dreyling, M
Gramatzki, M
Böck, HP
Haenel, M
Seymour, JF
Unterhalt, M
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 566S - 566S
[3] The addition of rituximab to a fludarabine combination (R-FCM) significantly improves remission rates and overall survival in recurrent follicular as well as mantle cell lymphoma - Followup of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
Dreyling, M
Forstpointner, R
Ludwig, W
Gramatzki, M
Boeck, H
Haenel, M
Wandt, H
Parwaresch, R
Unterhalt, M
Hiddemann, W
ANNALS OF ONCOLOGY, 2005, 16 : 110 - 111
[4] Rituximab maintenance after R-FCM salvage therapy in patients with follicular and mantle cell lymphomas - Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Unterhalt, M.
Forstpointner, R.
Dreyling, M.
Gramatzki, M.
Bock, H. P.
Hanel, Annette
Seymour, J.
Planker, M.
Duhrsen, U.
Wilms, K.
Clemens, M.
Ludwig, W. D.
Wandt, H.
Pasold, R.
Hiddemann, W.
ANNALS OF HEMATOLOGY, 2006, 85 : 36 - 37
[5] CHOP improves response rates but not overall survival in follicular and mantle cell lymphoma (MCL) -: Results of a randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
Nickenig, C
Dreyling, MH
Schiegnitz, E
Pfreundschuh, M
Truemper, LH
Reiser, M
Wandt, H
Lengfelder, E
Ludwig, WD
Berdel, WE
Metzner, B
Hess, G
Forstpointner, R
Parwaresch, R
Hasford, J
Unterhalt, M
Hiddemann, W
BLOOD, 2004, 104 (11) : 176A - 176A
[6] Rituximab maintenance prolongs response duration after salvage therapy with R-FCM in patients with relapsed follicular lymphomas and mantle cell lymphomas:: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
Hiddemann, W
Forstpointner, R
Dreyling, M
Gramatzki, M
Böck, HP
Hanel, M
Seymour, J
Planker, M
Dührsen, U
Wilms, K
Clemens, M
Ludwig, WD
Wandt, H
Pasold, R
Unterhalt, M
BLOOD, 2005, 106 (11) : 270A - 270A
[7] Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma -: Results of a prospective Randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Hiddemann, W
Dreyling, MH
Forstpointner, R
Kneba, M
Woermann, B
Lengfelder, E
Schmits, R
Reiser, M
Metzner, B
Schmitz, N
Truemper, L
Eimermacher, H
Parwaresch, R
BLOOD, 2003, 102 (11) : 104A - 104A
[8] Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -: results of a prospective randomized study of the German Low Grade Lymphoma Study Group
Forstpointner, R
Hänel, A
Repp, R
Hermann, S
Metzner, B
Pott, C
Hartmann, F
Rothmann, F
Böck, HP
Wandt, H
Unterhalt, M
Hiddemann, W
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (43) : 2253 - 2258
[9] Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
Lenz, G
Dreyling, M
Hoster, E
Wörmann, B
Dührsen, U
Metzner, B
Eimermacher, H
Neubauer, A
Wandt, H
Steinhauer, H
Martin, S
Heidemann, E
Aldaoud, A
Parwaresch, R
Hasford, J
Unterhalt, M
Hiddemann, W
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) : 1984 - 1992
[10] The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantel cell lymphomas (MCL) -: Results of a prospective randomized comparison of the German low grade study group (GLSG).
Hiddemann, W
Forstpointner, R
Fiedler, F
Gramatzki, M
Dörken, B
Illiger, HJ
Kneba, M
Pfreundschuh, M
Parsold, R
Parwaresch, R
Dreyling, M
Unterhalt, M
BLOOD, 2001, 98 (11) : 844A - 844A

← 1 2 3 4 5 →